Immunosuppressant effective in NMO
The immunosuppressant mycophenolate mofetil (MMF) reduces the frequency of relapses and improves disability scores in patients with neuromyelitis optica.
The drug cut the median annualised relapse rate from 1.5 to zero in an observational study of 59 patients with neuromyelitis optica spectrum disorder.
Sixty per cent of participants remained relapse-free over the study period and disability status scores were improved or remained stable in 91% of patients.
Overall, relapse rates were significantly reduced in 88% of